ATTR

BridgeBio terminates effort to acquire remainder of Eidos Therapeutics

BridgeBio, which already owns about 66 percent of Eidos, had initially offered to buy the company in August, but the proposed deal was rejected. Eidos is developing a drug in the competitive ATTR space.

By Alaric DeArment

BioPharma

FDA approves Pfizer’s Vyndaqel, Vyndamax for cardiomyopathy in rare protein disorder

An analyst wrote that the drug's high price tag of $225,000 could limit its uptake in ATTR-CM, but it could become competitive with Alnylam's Onpattro.

By Alaric DeArment